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Abstract
Recent population studies suggest an intriguing inverse relationship between several types of 
cancer and neurodegenerative diseases, including Alzheimer’s disease. Understanding the 
intersection of the underlying biology for these two distinct families of diseases with one another 
may offer novel approaches to identify new therapeutic approaches and possible opportunities to 
repurpose existing drug candidates. The Alzheimer’s Association and the Alzheimer’s Drug 
Discovery Foundation convened a one day workshop to delve into this discussion. Workshop 
participants outlined research focus areas, potential collaborations and partnerships for future 
action.
1. Introduction
Over the past decade, several population-based studies have suggested an intriguing 
relationship between many types of cancer and neurodegenerative diseases, including 
Alzheimer's disease (AD), and Parkinson’s disease (PD) and amyotrophic lateral sclerosis 
(ALS) (1). Both cancer and AD are heterogeneous diseases of aging that cause substantial 
morbidity and mortality. They receive substantial investment from both the National 
Institutes of Health (NIH) and the biotechnology/pharmaceutical industry. Success in 
translating biological discoveries about AD into new therapies lags far behind those 
achieved to date within the cancer field, an area of major foment with an explosion of 
interest in effective immune approaches.
The nexus of cancer and neurodegenerative disease may offer novel opportunities to expand 
understanding of disease-related mechanisms and identify new therapeutic targets. 
Recognizing these possibilities, the Alzheimer's Association and the Alzheimer's Drug 
Discovery Foundation (ADDF) convened a one-day think tank on May 25, 2016. Its purpose 
was to delve into the biological underpinnings that may provide further context for the 
inverse relationship between cancer and later-life neurodegenerative diseases, particularly 
AD and PD. Further, we explored whether and how these insights may be exploited to 
advance drug discovery. Participants in this discussion spanned the disciplines of 
biostatistics, epidemiology, genetics, immunology, neurology, neuropsychology, oncology, 
radiation oncology, psychiatry, and surgery.
2. Epidemiologic evidence linking cancer with neurodegenerative disease
Evidence from multiple epidemiological studies suggests a negative or inverse association: 
i.e., a lower risk of some cancers among persons with AD and PD (2), as well as a lower risk 
of subsequent AD among cancer survivors (3). Additional work has identified associations 
between other cancers and AD (4). Reduced risk of cancer has also been identified in 
patients with ALS (5), although no effect has been found on the risk of incident ALS 
following a diagnosis of cancer (6, 7). These associations appear across many individual 
types of cancer, including both smoking-related cancers (oral, breast, lung, pancreas, etc.) 
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and smoking-unrelated cancers. However, in PD, studies have also suggested positive or 
direct associations with melanoma and prostate cancer (8, 9).
Observational findings, even when remarkably consistent, are only signals; the challenge is 
to understand what mechanisms they represent. Methodological explanations may account 
for some of the observed reduced risk of cancer in patients with neurodegenerative disease. 
Three types of bias are particularly germane to this discussion. First, a competing risks or 
survival bias could result from poorer survival among patients with both AD or PD and 
cancer, compared to those with neurodegenerative disease alone. A second type of bias – 
ascertainment bias – would result from a difference in the likelihood of screening or 
detection of one disease after the diagnosis with the other. Indeed, a study by Freedman and 
colleagues suggested that PD patients are less likely to receive cancer screening and 
aggressive diagnostic procedures, and they concluded that the data do not support a 
biological relationship between PD and cancer (10). Finally, non-population-based studies 
may suffer from selection bias if, for example, people with cancer do not volunteer for 
dementia research, and vice versa.
When analyzing risk relationships between cancer and AD, the type of data available (e.g., 
from large database or multiple studies), study design, and analytic approaches, all influence 
results. For example, to take into account the relatively low frequency of both individual 
cancer types and the various neurodegenerative disorders, the sample must be large enough 
and follow-up sufficiently long with adequate assessment of both outcomes. The study may 
have a prospective cohort, nested case-control, or cross-sectional design, depending upon the 
data available and the selected study population (e.g., cancer registry, AD registry, or 
population-based cohort or registry). Analytic methods and inferences should vary according 
to the sample and design. For a time-to-event or survival analysis, the baseline must be 
clearly specified.
Interpreting signals from epidemiologic studies is challenging for multiple reasons in 
addition to the issues of bias discussed above. Multiple overlapping mechanisms and 
common risk factors appear to underlie both cancer and neurodegenerative disease. Further 
complicating this scenario is the fact that risk factors may be associated with either an 
increased or diminished risk of both some cancers and some neurodegenerative diseases. 
Epidemiologic studies also point to possible biological factors that could explain the 
observed association between cancer and neurodegenerative diseases, including common 
risk factors such as stress, obesity, diabetes, chronic inflammation, and immunosenescence 
(1). Stress itself can alter cancer immunity. For other risk factors, such as smoking, the 
associations may be in opposite directions: smoking is associated with a higher risk for some 
cancers and in some studies for AD, but a lower risk for PD (11, 12). Ethnicity and other 
environmental factors also play important roles in disease pathogenesis. In a Taiwanese 
study, for example, PD showed a positive rather than negative relationship with increased 
risk of all cancers (13). One possibility is that cultural bias, especially in terms of dementia, 
could affect diagnosis rates and thus the overall results. Vascular interactions could also play 
important roles, related to whether cancer survivors have an increased risk of metabolic 
disorders that may, in turn, increase their risk of vascular disease.
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Interactions among risk factors further complicate the picture. For example, the association 
between melanoma and PD appears to be biologically plausible, given that melanocytes and 
neurons both arise from a common embryonic cell type. In addition, levodopa (the 
predominant treatment for PD) serves as a substrate for the syntheses of both dopamine and 
melanin. Some studies have suggested that pigmentation gene polymorphisms may explain 
the increased risk of melanoma in PD patients (14). However, another study found no 
association between PD single-nucleotide polymorphisms (SNPs) and melanoma (15), and 
yet another study found no association of pigmentation phenotypes with PD (16). Thus, 
current evidence does not clearly support a genetic link, although sample sizes are 
underpowered to definitively support a negative statement. Environmental links are more 
difficult to assess in this context.
3. Mechanistic links between cancer and AD
Neoplasia and neurodegeneration share many genes and biological pathways, although they 
are often regulated in different directions (17, 18). The common pathways implicated in both 
cancer and neurodegenerative diseases include those that have an age-related change in 
regulation: cellular metabolism, inflammation, immunosenescence, oxidative stress, 
angiogenesis, DNA repair, apoptotic cell death and removal of effete proteins and organelles, 
and cell cycle entry. Aging is also associated with alterations in chaperone-mediated protein 
folding, and protein degradation. In support of the hypothesis that cellular molecular 
processes are dysregulated in opposite directions, Ibanez and colleagues conducted 
transcriptome meta-analyses of microarray gene expression data from three 
neurodegenerative diseases and three cancers, examining pathways that were down-
regulated in central nervous system (CNS) disorders and up-regulated in cancer, and vice 
versa. Metabolism and genetic information-processing pathways were most significantly 
down-regulated in CNS disorders and up-regulated in cancer (19). Holohan et al reviewed 
differential pathway regulation based on related microRNA based mechanisms in cancer and 
AD (18). The protective effect of cancer history in a person with AD behaves in a similar 
manner to genetic modulation of AD risk. Nudelman et al, analyzing ADNI data, found that 
individuals with a history of cancer demonstrated later onset age of symptoms of AD (20).
Some 60 years ago, Otto Warburg proposed that cancers arise as a result of metabolic 
dysfunction (21), suggesting that so-called oxidative glycolysis with dysfunctional 
mitochondria was central to the disease. Although this finding resulted in a Nobel Prize for 
the scientific team, it was many years before scientists began to appreciate the important role 
of mitochondrial function in the development and progression of cancer. Now, increasing 
evidence suggests that the inverse association between cancer and neurodegeneration may, at 
least in part, result from diametrically opposite bioenergetic requirements of neurons and 
cancer cells (22), neurons being post-mitotic and relying largely on oxidative 
phosphorylation (OXPHOS) and tumors arising with associated hypoxia and nutrient 
deprivation, with fermentative glycolytic pathways. Thus, in response to metabolic 
dysregulation, both cancer cells and neurons undergo metabolic reprogramming. Cancer 
cells up regulate glycolysis, while astrocytes and neurons up regulate OXPHOS, results in 
more reactive oxidation species and stress (23). Mitochondria are the cell’s primary 
generators of energy, and mitochondrial dysfunction occurs in aging as well as in many 
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diseases, including neurodegenerative diseases. Mitochondrial proteins are important in 
cerebral remodeling (24) and common proteins involved with mitochondrial quality control 
are disordered in the setting of neurodegeneration and cancer (25). Mitochondria may also 
play a role in the development of cancer and neurodegenerative diseases (26) through 
cellular energy deficits and oxidative stress pathways (27), by emergent mitochondrial 
heteroplasmy (28, 29) and effective mismatch between the mitochondrial and nuclear 
genomes present throughout the lifetime of the individual (30).
Aging is typically associated with changes in immune function; in particular a more 
activated innate immune system and increased inflammatory profile combined with 
immunosenescence or the decline of adaptive immunity and immune exhaustion. Indeed, 
immunosenesence coincides with the onset of AD and many cancers, and the immune 
system, including brain resident microglia and astrocytes, appears to contribute significantly 
to neurodegenerative pathology (31). A recent effort called the Immune Variation (ImmVar) 
project is seeking to map the genetic variation that leads to variation in immune function in 
healthy subjects, as a first step in understanding how such variations contribute to various 
diseases, including AD and PD (32, 33). In addition, studies aimed at dissecting the role of 
the immune component of mRNA-derived molecular networks of the aging human cortex 
are ongoing (34). These integrative approaches provide an unsupervised evaluation of all 
cells in the target cortical tissue, and, in combination with longitudinal profiling of 
peripheral blood and deep phenotypic characterization of individuals with neurodegenerative 
disease and cancer, they should provide a new framework with which to better understand 
how systemic and brain immune function affect one another in making a person susceptible 
to AD and/or cancer.
Molecular chaperones – in particular heat-shock proteins (HSPs) – regulate the folding and 
unfolding of proteins. HSPs are regulated by the heat shock transcription factor 1(HSF-1) 
and are abundantly expressed in many cancer cells, but their synthesis declines with age in 
neuronal cells. In cancer, HSP72, for example, has been linked to breast cancer progression 
and tumor initiation, growth and metastasis in lung cancer. Thus, HSPs and HSF-1 have 
been implicated as attractive therapeutic targets. Molecular chaperones can also be secreted, 
whereupon they carry out extracellular functions, including those related to immune and 
inflammatory modulation and wound healing. Another abundant nuclear protein, HMGB1 is 
associated with both neurodegeneration and cancer (35).
Aging is associated with the loss of the sex steroid hormones, estrogens in women and 
testosterone in men. Sex hormones have also been linked to cognitive function and cancer, 
particularly of the breast (36), but also other cancers such as colorectal cancer (37). A 
positive association has also been found between prostate cancer and both Alzheimer's and 
PD dementia (9). The relationship between sex hormones and neurodegeneration is 
complicated, since estrogens and androgens exert both positive and negative effects in the 
brain (38, 39). However, the age-related loss of sex hormones – such as loss of estrogen in 
women and testosterone in men - is associated with an increased risk of AD as well as 
increase levels of β-amyloid levels, increased tau phosphorylation,, increased neuronal 
death, and decreased spine density (38).
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Sex hormones have also been linked to the development of certain cancers. For instance, 
estrogens are well-known drivers of tumor proliferation in hormone-receptor positive breast 
cancer (40), and androgens are known to play a similar role in the pathogenesis of prostate 
cancer (41). Given their critical roles in the development of breast and prostate cancer 
respectively, therapies that modulate or inhibit estrogen and testosterone have become 
mainstays of treatment for these diseases. Endocrine therapies, including selective estrogen 
receptor modulators (SERM), such as tamoxifen, and aromatase inhibitors, have 
dramatically improved survival in women with hormone-receptor positive breast cancer (42). 
However, the anti-estrogen properties of both of these endocrine therapies can exert negative 
effects on the brain, and endocrine therapy use is positively associated with impairment on a 
number of cognitive domains (43). Similarly, while androgen deprivation therapy 
significantly improves prostate cancer outcomes, treatment has also been associated with 
negative effects on visuomotor ability (44) and there is evidence that androgen deprivation 
therapy may increase the risk of developing AD (45).
Complicating the inverse relationship of cancer with neurodegenerative disease is the fact 
that cancer treatments like chemotherapy may accelerate aging effects. Chemotherapy for 
cancer has been associated with inconsistent effects on cognitive impairment, although there 
appear to be parallels between the biology of aging and the effects of chemotherapy (47, 48). 
Structural, functional and molecular imaging approaches similar to those used in AD 
research have been employed in studies of cancer patients (49). There is also evidence that 
chemotherapy may impact brain regions associated with brain aging (49–51). Thus, when 
examining the mechanisms underlying the association between cancer, AD and related 
dementia, the adverse cognitive effects of chemotherapy and hormonal cancer treatments 
should also be considered.
4. Genetic links between cancer and AD
Genes that are implicated in both cancer and neurodegenerative disease may provide clues 
about pathogenic mechanisms as well as point to potential therapeutic targets. For example, 
the breast and ovarian cancer type 1 susceptibility gene (BRCA1) encodes a DNA repair 
protein, BRCA1. BRCA1 is expressed at reduced levels in the brains of individuals with AD 
and in animal models of AD. Beta-amyloid (Aβ) oligomers reduce BRCA1 levels in 
neuronal cultures, and BRCA1 depletion in mice is associated with impaired cognitive 
function (52). It is not yet known whether mutations in BRCA1 would change its function in 
the brain. In addition, the APOE e2 allele which reduces risk of AD may increase risk and 
aggressiveness of some cancers (64).
APOEε4 is the strongest genetic risk factor for late onset AD (53). Presence of the ε4 
haplotype is also associated with poor cognitive function following chemotherapy, possibly 
because of impaired neural repair mechanisms (54). Recently, bexarotene, a drug developed 
to treat skin cancer that targets the expression of APOE, has shown promise in AD mouse 
models, both clearing Aβ and reversing cognitive, social, and olfactory deficits (55). A proof 
of concept phase 2 clinical trial of this drug did not suggest a benefit of the drug compared 
with placebo and highlighted potential cardiovascular adverse events (56).
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Other genes that have been linked to both cancer and AD include tumor suppressor genes, 
including BIN1 (57), the transmembrane receptor gene expressed on myeloid cells TREM2 
(58), and genes involved in cell-cycle and angiogenesis transcriptional signaling, pathways 
(59). A mutation in the gene LRRK2, which is associated with increased PD susceptibility 
has also been shown to increase the risk of certain cancers (60).
5. Drug repurposing and other therapeutic implications
Although AD and cancer share biological targets, approaches to these targets may be 
opposing for these different indications. For example, proteasome inhibitors may be 
effective anti-cancer drugs, while proteasome activators may be useful in slowing 
neurodegeneration. Some cancer treatments may target proliferation by promoting apoptosis, 
while AD treatments might seek to protect neurons and limit cell death. Alternatively, 
pathways affected in AD and cancer can also be similarly regulated – for example certain 
epigenetic changes may both cause neurodegeneration and contribute to cancer. As 
experimental agents for cancer are applied to neurodegenerative disease, there will be a need 
to make these agents more brain penetrable, safe, and effective at lower doses to enable 
chronic dosing.
Repurposing of cancer chemotherapeutics already on the market offers a possible 
accelerated pathway to new drugs for AD (61). A number of cancer drugs that target 
mechanisms important in neurodegeneration have been proposed for repurposing, including 
tyrosine kinase inhibitors, immune checkpoint inhibitors (62), liver X receptor and retinoid 
X receptor (LXR/RXR) agonists that target lipid-transport proteins such as APOE, and 
microtubule stabilizers. Conversely, as AD treatments focused on these targets are 
developed, there is also the potential for these therapies to benefit cancer patients.
6. Conclusions/next steps
Both cancer and AD are complex, polygenic diseases in which multiple overlapping 
pathways are implicated. The apparent links between these diseases suggest possible 
therapeutic options and the testing of cancer treatments for AD, as well as the need for 
deeper investigation into the cognitive side effects of cancer treatments and the long term 
implications (63).
While there may be a few immediate opportunities for repurposing clinical trials of cancer 
drugs for neurodegenerative disease, workshop participants agreed that a better 
understanding of underlying mechanisms between these diseases is needed. This includes a 
more thorough understanding of the biological heterogeneity that characterizes both 
neurodegenerative diseases and cancers. Further work to elucidate the biological 
underpinnings of these diseases will also help in terms of detection, biomarker development, 
the development of pharmacological and non-pharmacological interventions, and prevention. 
A systems biology approach to answering these questions could be applied to address the 
inherent complexity and overlapping features of these diseases.
Discussion focused on identifying the potential avenues of exploration that could leverage 
learnings and existing resources in the oncology space to neurodegenerative diseases and 
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vice versa. For instance, in the U.S., the National Cancer Institute (NCI) supports a 
Surveillance, Epidemiology, and End Results (SEER) Program, which collects data on 
cancer incidence and survival in some parts of the country. A SEER equivalent for AD, even 
if adopted in only one or two of the same areas of the country, could provide similar 
resources in the AD field. Exploring genetic links between neurodegenerative disease and 
cancer is feasible, but, given the variability within AD and PD patient populations, sample 
size requirements are significant. European population-based registries provide a potential 
resource for exploring these avenues more powerfully. Areas of research that would 
significant enhance our understanding and provide a framework for advancing research 
toward applying therapeutic approaches from cancer to neurodegenerative disease were 
discussed. Identified research priorities include:
• Explore existing cancer cohort studies with AD biomarker studies including 
genetics and genomics, blood and CSF analytes, and advanced neuroimaging. 
Conversely, new studies could include more comprehensive assessment of cancer 
data in cohorts addressing aging related cognition and MR imaging outcomes.
• Develop systematic, longitudinal immunoprofiling of the human peripheral and 
resident immune system in subjects with deep phenotypic characterization 
relevant to AD pathology and cancer, to understand how systemic and brain 
immune function affect one another in making someone susceptible to AD and 
cancer.
• Develop longitudinal characterization of immunosenescence to understand 
immune system dynamics and identify biomarkers with which to measure innate 
immune function that is relevant to cancer and AD.
• Invest in large-scale functional and compound screening of novel human in vitro 
systems to understand and perturb the functional consequences of genetic and 
other AD risk factors in immune cells.
• Develop comprehensive phenotyping across multiple domains of available 
cohorts through collaborations between NCI, NIA, and other agencies.
• Identify well-characterized cohorts of young adults and following them through 
late adulthood with a life course approach to simultaneously identify and track 
the development of both cancer and neurodegeneration, including their risk 
factors and preclinical marker.
• Identify common or variant biomarkers that reflect the two diseases
More immediate needs include a toolkit for immune profiling and the development of 
pharmacodynamic markers for AD. To learn from what has been achieved in the cancer field 
and transfer these lessons to AD, these and other initiatives will require consortia of 
government and non-profits as well as policy innovations to stimulate investment in 
repurposed drug evaluation for AD and other neurodegenerative diseases.
As the cancer survivorship population grows, issues related to the long term effects of 
chemotherapy on cognition will also become more and more important. To understand these 
effects, as well as how other exposures in mid-life may impact both cancer and 
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neurodegenerative disease in combination, funding agencies will also need to support long-
lasting longitudinal studies. Taken together, the current evidence along with the strong 
scientific rationale for future investigations supports the need to understand the nexus 
between cancer and neurodegeneration, including Alzheimer’s disease, and to translate this 
information to therapy learnings for potential future clinical trials.
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Research in context
Systematic Review
Recent population studies suggest an intriguing inverse relationship between several 
types of cancer and neurodegenerative diseases, including Alzheimer’s disease.
Interpretation
Understanding the intersection of the underlying biology for these two distinct families of 
diseases with one another may offer novel approaches to identify new therapeutic 
approaches and possible opportunities to repurpose existing drug candidates. During this 
one day workshop, experts explored the nexus of biological mechanisms – inflammation, 
cell cycle regulation, cell survival, and others – to identify potential targets for future 
investigation.
Future Directions
Workshop participants outlined research focus areas, potential collaborations and 
partnerships for future action. Discussion focused on identifying the potential avenues of 
exploration that could leverage learnings and existing resources in the oncology space to 
neurodegenerative diseases and vice versa.
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